TY - JOUR
T1 - Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy
AU - Gurol, M. Edip
AU - Dierksen, Gregory
AU - Betensky, Rebecca
AU - Gidicsin, Christopher
AU - Halpin, Amy
AU - Becker, Alex
AU - Carmasin, Jeremy
AU - Ayres, Alison
AU - Schwab, Kristin
AU - Viswanathan, Anand
AU - Salat, David
AU - Rosand, Jonathan
AU - Johnson, Keith A.
AU - Greenberg, Steven M.
N1 - Funding Information:
M.E. Gurol receives research support from the NIH (T32NS048005, R01 NS070834-02). G. Dierksen reports no disclosures. R. Betensky has received funding from NIH for the development of statistical methodology and for collaborations in brain tumors, stroke, CAA, Alzheimer disease, cancer, and multiple sclerosis. She has received funding from the Harvard NeuroDiscovery Center and the Harvard Catalyst (CTSA) for statistical support of collaborative projects. She has received funding from Bristol Myers Squibb and NIH for DSMB service, from Novartis for statistical methodology development with applications to MS, and from Maine Medical Center, Arex, Sekisui, Gerson Lehrman Group, Leerink Swann, Guidepoint Global, HLM Venture Partners, Clinical Trials Solutions, and Cowen Inc. for general statistical consultation. C. Gidicsin, A. Halpin, A. Becker, J. Carmasin, A. Ayres, K. Schwab, A. Viswanathan, D. Salat, J. Rosand, and K.A. Johnson report no disclosures. S.M. Greenberg served on Scientific Advisory Boards (1-NINDS Data Safety Monitoring Board for clinical trials in intracerebral hemorrhage, 2-Hoffman-Laroche, MRI Review Committee) and has received funding for travel or speaker honoraria (Medtronics, research lecture, 2010 Pfizer Global Research and Development, research lecture, 2010). Dr. Greenberg is also on the editorial boards of several journals (Stroke, Editorial Board, 2010–present; Cerebrovascular Disease, Editorial Board, 2008–present; Neurology®, Editorial Board, 2005–present; Journal of Alzheimer's Disease and Other Dementias, Editorial Board, 2005–present). Dr. Greenberg worked as a consultant for Hoffman-LaRoche, Janssen Alzheimer Immunotherapy, and Bristol-Myers Squibb Company. He received research support from the NIH. Go to Neurology.org for full disclosures.
Funding Information:
Study funding: Supported by NIH (T32NS048005, 5R01NS070834-01/02, R01AG026484).
PY - 2012/7
Y1 - 2012/7
N2 - We aimed to determine whether amyloid imaging can help predict the location and number of future hemorrhages in cerebral amyloid angiopathy (CAA). We performed a longitudinal cohort study of 11 patients with CAA without dementia who underwent serial brain MRIs after baseline amyloid imaging with Pittsburgh compound B (PiB). Mean distribution volume ratio (DVR) of PiB was determined at the sites of new micro/macrobleeds identified on follow-up MRI and compared with PiB retention at “simulated” hemorrhages, randomly placed in the same subjects using a probability distribution map of CAA-hemorrhage location. Mean PiB retention at the sites of observed new bleeds was also compared to that in shells concentrically surrounding the bleeds. Finally the association between number of incident bleeds and 3 regional amyloid measures were obtained. Nine of 11 subjects had at least one new microbleed on follow-up MRI (median 4, interquartile range [IQR] 1-9) and 2 had 5 new intracerebral hemorrhages. Mean DVR was greater at the sites of incident bleeds (1.34, 95% confidence interval [CI] 1.23-1.46) than simulated lesions (1.14, 95% CI 1.07-1.22, p < 0.0001) in multivariable models. PiB retention decreased with increasing distance from sites of observed bleeds (p < 0.0001). Mean DVR in a superior frontal/parasagittal region of interest correlated independently with number of future hemorrhages after adjustment for relevant covariates (p = 0.003). Our results provide direct evidence that new CAA-related hemorrhages occur preferentially at sites of increased amyloid deposition and suggest that PiB-PET imaging may be a useful tool in prediction of incident hemorrhages in patients with CAA. Aβ: β-amyloid CAA: cerebral amyloid angiopathy CI: confidence interval DVR: distribution volume ratio IQR: interquartile range PiB: Pittsburgh compound B ROI: region of interest SWI: susceptibility-weighted imaging.
AB - We aimed to determine whether amyloid imaging can help predict the location and number of future hemorrhages in cerebral amyloid angiopathy (CAA). We performed a longitudinal cohort study of 11 patients with CAA without dementia who underwent serial brain MRIs after baseline amyloid imaging with Pittsburgh compound B (PiB). Mean distribution volume ratio (DVR) of PiB was determined at the sites of new micro/macrobleeds identified on follow-up MRI and compared with PiB retention at “simulated” hemorrhages, randomly placed in the same subjects using a probability distribution map of CAA-hemorrhage location. Mean PiB retention at the sites of observed new bleeds was also compared to that in shells concentrically surrounding the bleeds. Finally the association between number of incident bleeds and 3 regional amyloid measures were obtained. Nine of 11 subjects had at least one new microbleed on follow-up MRI (median 4, interquartile range [IQR] 1-9) and 2 had 5 new intracerebral hemorrhages. Mean DVR was greater at the sites of incident bleeds (1.34, 95% confidence interval [CI] 1.23-1.46) than simulated lesions (1.14, 95% CI 1.07-1.22, p < 0.0001) in multivariable models. PiB retention decreased with increasing distance from sites of observed bleeds (p < 0.0001). Mean DVR in a superior frontal/parasagittal region of interest correlated independently with number of future hemorrhages after adjustment for relevant covariates (p = 0.003). Our results provide direct evidence that new CAA-related hemorrhages occur preferentially at sites of increased amyloid deposition and suggest that PiB-PET imaging may be a useful tool in prediction of incident hemorrhages in patients with CAA. Aβ: β-amyloid CAA: cerebral amyloid angiopathy CI: confidence interval DVR: distribution volume ratio IQR: interquartile range PiB: Pittsburgh compound B ROI: region of interest SWI: susceptibility-weighted imaging.
UR - http://www.scopus.com/inward/record.url?scp=84867880031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867880031&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e31826043a9
DO - 10.1212/WNL.0b013e31826043a9
M3 - Article
C2 - 22786597
AN - SCOPUS:84867880031
SN - 0028-3878
VL - 79
SP - 320
EP - 326
JO - Neurology
JF - Neurology
IS - 4
ER -